Topical Minoxidil and Low‐Dose Oral Minoxidil in Onychodystrophy: A Proposed Treatment Algorithm
Journal of Cosmetic Dermatology · 2026-04 · 25 (4)
DOI: 10.1111/jocd.70863 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Cosmetic Dermatology, online erschienen am 19.04.2026. Verfasst von Aditya K Gupta und 2 weiteren Autor:innen. Beteiligte Einrichtung: Mediprobe Research Inc., London, Ontario, Canada. Hauptthemen laut MEDLINE: Minoxidil, Nail Diseases, Vasodilator Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Onychodystrophy includes diverse nail disorders that may impair function and quality of life. Because nails grow slowly, adjunctive therapies that promote nail growth are of increasing interest.
Aim
This review examines the evidence for minoxidil in nail growth and nail disorders and proposes a treatment algorithm for its adjunctive use in onychodystrophy.
Method
A structured search of PubMed and Google Scholar was conducted on December 10, 2025, using terms related to minoxidil and nails. Records were deduplicated, screened, and appraised by full‐text review using the Oxford Centre for Evidence‐Based Medicine 2009 levels.
Results
A potential adjunctive treatment algorithm is proposed, emphasizing treatment of the underlying nail disorder first. Topical minoxidil (2% or 5% solution or foam, applied once or twice daily to the proximal nail fold) or low‐dose oral minoxidil (LDOM; 0.625–2.5 mg/day in females and 1.25–5 mg/day in males) may then be considered, with appropriate monitoring and discontinuation criteria. Safety data for topical use indicate predominantly local irritation, whereas LDOM has been associated with tachycardia, edema, and other systemic adverse effects. Minoxidil may support nail growth through KATP channel‐mediated vasodilation and growth factor signaling, with downstream activation of the Wnt/β‐catenin pathway.
Conclusion
Minoxidil shows potential as an adjunct to support nail growth, but nail‐disorder–specific evidence remains limited. Controlled trials are needed to define efficacy, optimal regimens, and safety in onychodystrophy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Mediprobe Research Inc., London, Ontario, Canada.
- Division of Dermatology, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
- School of Pharmacy, BRAC University, Dhaka, Bangladesh.
- Department of Dermatology, Weill Cornell Medicine, New York City, New York, USA.
ORCID-Profile: Aditya K Gupta, Mesbah Talukder, Shari R Lipner
Zitieren
APA
Gupta, A. K., Talukder, M., & Lipner, S. R. (2026). Topical Minoxidil and Low‐Dose Oral Minoxidil in Onychodystrophy: A Proposed Treatment Algorithm. Journal of Cosmetic Dermatology, 25(4). https://doi.org/10.1111/jocd.70863
Vancouver
Gupta AK, Talukder M, Lipner SR. Topical Minoxidil and Low‐Dose Oral Minoxidil in Onychodystrophy: A Proposed Treatment Algorithm. Journal of Cosmetic Dermatology. 2026;25(4). doi:10.1111/jocd.70863
BibTeX
@article{Gupta2026,
author = {Gupta, Aditya K and Talukder, Mesbah and Lipner, Shari R},
title = {Topical Minoxidil and Low‐Dose Oral Minoxidil in Onychodystrophy: A Proposed Treatment Algorithm},
journal = {Journal of Cosmetic Dermatology},
year = {2026},
volume = {25},
number = {4},
doi = {10.1111/jocd.70863}
}
EUVIMED